IP Library Granted Patent US 8,216,565
Granted Patent B2
US 8,216,565 · App. 12/522,321 · Granted Jul 10, 2012

GP100-specific T cell receptors and related materials and methods of use

Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,565
App. No.
12/522,321
Granted
Jul 10, 2012
Kind
B2
Abstract

The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.

Claims (9)

1. A human cell comprising a murine T Cell Receptor (TCR) comprising one or more of the amino acid sequences selected from the group consisting of SEQ ID NOs: 2 to 9.

2. The human cell of claim 1 , wherein the cell is a T cell.

3. The human cell of claim 1 , wherein the TCR has antigenic specificity for amino acids 154-162 of human gp100 SEQ ID NO: 1.

4. The human cell of claim 1 , wherein the TCR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 17.

5. The human cell of claim 1 , wherein the TCR comprises SEQ ID NO: 2 and SEQ ID NO: 3.

6. A population of cells comprising at least one human cell of claim 1 .

7. A conjugate comprising the human cell of claim 1 and a therapeutic agent, a detectable moiety, or both a therapeutic agent and a detectable moiety.

8. The conjugate of claim 7 , wherein the therapeutic agent is an anti-cancer therapeutic agent.

9. A pharmaceutical composition comprising the human cell of claim 1 , and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2009
From: RESTIFO, NICHOLAS P.; CASSARD, LYDIE; YU, ZHIYA; ROSENBERG, STEVEN A.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 023083/0358 →
Continuity (3)
Provisional Application 60884732 · Jan 12, 2007
Provisional Application 60885724 · Jan 19, 2007
Related Publication 20100015113A1 · Jan 21, 2010